Literature DB >> 30370295

Recombinant poliovirus for cancer immunotherapy.

Millena Prata Jammal1, Márcia Antoniazi Michelin2, Rosekeila Simões Nomelini1, Eddie Fernando Candido Murta1.   

Abstract

Entities:  

Year:  2018        PMID： 30370295      PMCID： PMC6186568          DOI： 10.21037/atm.2018.07.19

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Dendritic cells and macrophages are productively infected by poliovirus.

Authors:  Rahnuma Wahid; Martin J Cannon; Marie Chow
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 2.  Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation.

Authors:  Yoshimi Takai; Jun Miyoshi; Wataru Ikeda; Hisakazu Ogita
Journal:  Nat Rev Mol Cell Biol       Date:  2008-08       Impact factor: 94.444

3.  Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Authors:  Vidyalakshmi Chandramohan; Jeffrey D Bryant; Hailan Piao; Stephen T Keir; Eric S Lipp; Michaela Lefaivre; Kathryn Perkinson; Darell D Bigner; Matthias Gromeier; Roger E McLendon
Journal:  Arch Pathol Lab Med       Date:  2017-08-22       Impact factor: 5.534

4.  Clinical significance of CD155 expression in human pancreatic cancer.

Authors:  Satoshi Nishiwada; Masayuki Sho; Satoshi Yasuda; Keiji Shimada; Ichiro Yamato; Takahiro Akahori; Shoichi Kinoshita; Minako Nagai; Noboru Konishi; Yoshiyuki Nakajima
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

Review 5.  Adoptive cell transfer as personalized immunotherapy for human cancer.

Authors:  Steven A Rosenberg; Nicholas P Restifo
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 6.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

7.  Intergeneric poliovirus recombinants for the treatment of malignant glioma.

Authors:  M Gromeier; S Lachmann; M R Rosenfeld; P H Gutin; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

8.  Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo.

Authors:  Hidemi Toyoda; Eckard Wimmer; Jeronimo Cello
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

Review 9.  Oncolytic polio virotherapy of cancer.

Authors:  Michael C Brown; Elena Y Dobrikova; Mikhail I Dobrikov; Ross W Walton; Sarah L Gemberling; Smita K Nair; Annick Desjardins; John H Sampson; Henry S Friedman; Allan H Friedman; Douglas S Tyler; Darell D Bigner; Matthias Gromeier
Journal:  Cancer       Date:  2014-06-17       Impact factor: 6.860

10.  Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Authors:  Eda K Holl; Michael C Brown; David Boczkowski; Megan A McNamara; Daniel J George; Darell D Bigner; Matthias Gromeier; Smita K Nair
Journal:  Oncotarget       Date:  2016-11-29
View more
  1 in total

Review 1.  Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.

Authors:  June Kyu Hwang; JinWoo Hong; Chae-Ok Yun
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.